Beijing Tide Pharmaceutical Co. Ltd. has patented new cathepsin C (dipeptidyl peptidase I) inhibitors reported to be useful for the treatment of bronchiectasis.
Beijing Tide Pharmaceutical Co. Ltd. has divulged nanobody-drug conjugates comprising a nanobody targeting B7 homolog 3 (B7-H3, CD276) covalently bound to exatecan through a linker reported to be useful for the treatment of lung cancer.
Beijing Tide Pharmaceutical Co. Ltd. has identified protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer and myelofibrosis.
Beijing Tide Pharmaceutical Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising a cereblon E3 ubiquitin ligase binding moiety coupled to tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) targeting agents through linkers reported to be useful for the treatment of cancer.
Beijing Tide Pharmaceutical Co. Ltd. has described orydalmine derivatives reported to be useful for the treatment of pain, depression, and substance abuse and dependence.
Work at Beijing Tide Pharmaceutical Co. Ltd. has led to the development of proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety coupled to an EGFR (HER1; erbB1)-targeting moiety through a linker.
Beijing Tide Pharmaceutical Co. Ltd. has prepared proteolysis-targeting chimera (PROTAC) compounds comprising an ubiquitin ligase binding moiety bound to a protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) targeting moiety through a linker.
Beijing Tide Pharmaceutical Co. Ltd. proteolysis-targeting chimera (PROTAC) compounds comprising a ubiquitin ligase-binding moiety bonded to a protein phosphatase nonreceptor type 11 (PTPN11)-targeting moiety through a linker.
